EA201590325A1 - Улучшенные способы лечения рака с пониженной почечной токсичностью - Google Patents

Улучшенные способы лечения рака с пониженной почечной токсичностью

Info

Publication number
EA201590325A1
EA201590325A1 EA201590325A EA201590325A EA201590325A1 EA 201590325 A1 EA201590325 A1 EA 201590325A1 EA 201590325 A EA201590325 A EA 201590325A EA 201590325 A EA201590325 A EA 201590325A EA 201590325 A1 EA201590325 A1 EA 201590325A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer treatment
renal toxicity
reduced renal
improved cancer
cancer patient
Prior art date
Application number
EA201590325A
Other languages
English (en)
Russian (ru)
Inventor
Тени Боуликас
Джордж Статопоулос
Original Assignee
Тени Боуликас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тени Боуликас filed Critical Тени Боуликас
Publication of EA201590325A1 publication Critical patent/EA201590325A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EA201590325A 2012-08-13 2012-08-13 Улучшенные способы лечения рака с пониженной почечной токсичностью EA201590325A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/050630 WO2014027996A1 (en) 2012-08-13 2012-08-13 Improved methods for treating cancer with reduced renal toxicity

Publications (1)

Publication Number Publication Date
EA201590325A1 true EA201590325A1 (ru) 2015-09-30

Family

ID=50101360

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590325A EA201590325A1 (ru) 2012-08-13 2012-08-13 Улучшенные способы лечения рака с пониженной почечной токсичностью

Country Status (13)

Country Link
US (1) US20150258140A1 (enExample)
EP (1) EP2882420A4 (enExample)
JP (1) JP2015528446A (enExample)
CN (1) CN104736143A (enExample)
AU (1) AU2012387681A1 (enExample)
BR (1) BR112015003111A2 (enExample)
CA (1) CA2882156A1 (enExample)
EA (1) EA201590325A1 (enExample)
IN (1) IN2015KN00375A (enExample)
MA (1) MA37931A1 (enExample)
SG (1) SG11201501146VA (enExample)
WO (1) WO2014027996A1 (enExample)
ZA (1) ZA201501123B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2654484C1 (ru) * 2012-05-11 2018-05-21 Ресет Терапьютикс, Инк. Карбазолсодержащие сульфонамиды в качестве модуляторов криптохрома

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04169532A (ja) * 1990-11-01 1992-06-17 Sumitomo Pharmaceut Co Ltd 脂溶性白金錯体含有リポソーム製剤
JPH04169531A (ja) * 1990-11-01 1992-06-17 Sumitomo Pharmaceut Co Ltd 脂溶性白金錯体を含有するリポソーム製剤
EP0551169A1 (en) * 1992-01-10 1993-07-14 Takeda Chemical Industries, Ltd. Liposome composition and production thereof
EP0929293B1 (en) * 1996-08-23 2003-10-22 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
DE19954613A1 (de) * 1999-11-12 2001-05-17 Enthone Omi Deutschland Gmbh Verfahren zur stromlosen Verzinnung von Kupfer oder Kupferlegierungen
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
US20120197060A1 (en) * 2009-06-18 2012-08-02 University Of Utah Research Foundation Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy technology

Also Published As

Publication number Publication date
BR112015003111A2 (pt) 2017-10-10
SG11201501146VA (en) 2015-05-28
CN104736143A (zh) 2015-06-24
JP2015528446A (ja) 2015-09-28
WO2014027996A1 (en) 2014-02-20
MA37931A1 (fr) 2016-07-29
EP2882420A1 (en) 2015-06-17
EP2882420A4 (en) 2016-06-01
ZA201501123B (en) 2020-02-26
US20150258140A1 (en) 2015-09-17
CA2882156A1 (en) 2014-02-20
IN2015KN00375A (enExample) 2015-07-10
AU2012387681A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
HK1221148A1 (zh) 包含tor激酶抑制剂和imid化合物的联合疗法用於治疗癌症
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
NZ716473A (en) Diagnosis and therapy of cancer involving cancer stem cells
PH12014502046B1 (en) Treatment of cancer with tor kinase inhibitors
MX2020004689A (es) Tratamiento del cancer con inhibidores de tor cinasa.
PH12016502354A1 (en) Pharmaceutical composition
PH12014502047B1 (en) Treatment of cancer with tor kinase inhibitors
PH12014502029B1 (en) Treatment of cancer with tor kinase inhibitors
MD20160016A2 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
HK1221150A1 (zh) 用二氢吡嗪并-吡嗪类对癌症的治疗
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
EA201590325A1 (ru) Улучшенные способы лечения рака с пониженной почечной токсичностью
PH12014502464A1 (en) Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
EA201491629A1 (ru) Способы лечения рака с использованием липоплатина
UA88769U (uk) Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності